Adibzadeh S.Amiri S.Nia G.E.Taleghani M.R.Bijarpas Z.K.Maserat N.Maali A.2023-01-122023-01-122022245201442452-0144https://doi.org/10.1016/j.genrep.2022.101619https://hdl.handle.net/11454/79545Coronavirus disease 2019 (COVID-19) is a remarkably contagious and pathogenic viral infection arising from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan, China. For the time being, COVID-19 is not treated with a specific therapy. The Food and Drug Administration (FDA) has approved Remdesivir as the first drug to treat COVID-19. However, many other therapeutic approaches are being investigated as possible treatments for COVID-19. As part of this review, we discussed the development of various drugs, their mechanism of action, and how they might be applied to different cases of COVID-19 patients. Furthermore, this review highlights an update in the emergence of new prophylactic or therapeutic vaccines against COVID-19. In addition to FDA or The World Health Organization (WHO) approved vaccines, we intended to incorporate the latest published data from phase III trials about different COVID-19 vaccines and provide clinical data released on the networks or peer-review journals. © 2022en10.1016/j.genrep.2022.101619info:eu-repo/semantics/openAccessAntiviral agentsCOVID-19PandemicsPneumoniaSARS-CoV-2Vaccines2019ncov hr 2pangiotensin converting enzyme 2anti-SARS-CoV-2 agentantibiotic agentbamlanivimabcamostat mesilatecasirivimab plus imdevimabchloroquinecoronavirus spike glycoproteincorticosteroiddalbavancindanopreviretesevimabfavipiravirhydroxychloroquineimmunomodulating agentinactivated vaccineinterferonivermectinlopinavirmetforminmolnupiravirnafamstat mesilatenelfinavirnirmatrelvirpeptiderecombinant angiotensin converting enzyme 2regen covremdesivirRNA vaccineSARS-CoV-2 antibodySARS-CoV-2 convalescent plasmaSARS-CoV-2 vaccinesid 26681509siltuximabsintilimabsotrovimabsubunit vaccinethioctic acidtocilizumabumifenovirunclassified drugvector vaccineantibiotic therapycoronavirus disease 2019corticosteroid therapyhumannonhumanReviewSevere acute respiratory syndrome coronavirus 2vaccinationvirus cell membrane fusionvirus endocytosisvirus entryReview272-s2.0-85129696305Q4